WO2002030359A2 - Procedes de lyse du sang coagule avec de le phenotype d'apolipoproteine e2 - Google Patents

Procedes de lyse du sang coagule avec de le phenotype d'apolipoproteine e2 Download PDF

Info

Publication number
WO2002030359A2
WO2002030359A2 PCT/US2001/042719 US0142719W WO0230359A2 WO 2002030359 A2 WO2002030359 A2 WO 2002030359A2 US 0142719 W US0142719 W US 0142719W WO 0230359 A2 WO0230359 A2 WO 0230359A2
Authority
WO
WIPO (PCT)
Prior art keywords
apo
clot
clot lysis
individual
blood
Prior art date
Application number
PCT/US2001/042719
Other languages
English (en)
Other versions
WO2002030359A3 (fr
Inventor
Joseph Broderick
Joseph Clark
Daniel Woo
Original Assignee
University Of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Cincinnati filed Critical University Of Cincinnati
Priority to AU2002214644A priority Critical patent/AU2002214644A1/en
Priority to US10/398,880 priority patent/US7208288B2/en
Publication of WO2002030359A2 publication Critical patent/WO2002030359A2/fr
Publication of WO2002030359A3 publication Critical patent/WO2002030359A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator

Definitions

  • This invention was made, at least in part, with funds from the Federal
  • This invention relates to methods for enhancing the lysis of coagulated blood and to methods for reducing the risk of blood coagulation by administration of a clot lysis agent and apolipoprotein E2.
  • the invention further relates to methods for enhancing the lysis of coagulated blood and methods for reducing the risk of blood coagulation by administration of a specific level of clot lysis agent based upon the apolipoprotein phenotype of the individual.
  • Thrombolytic therapy is a term known generally to reference treatment procedures for individuals with ischemic diseases or other perfusion disorders.
  • Many thrombolytic therapies comprise administering a clot lysis agent to affect the lysis of coagulated blood, i.e. blood clots.
  • Various clot lysis agents and their associated therapeutic derivatives are known to be effective to stimulate the lysis of coagulated blood.
  • Clot lysis agents known to enhance the lysis of coagulated blood include, but are not limited to, TNK-t-PA, tissue plasminogen activator (t-PA), reteplase, streptokinase, heparin, coumadin, Glib Ilia receptor blockers, and their therapeutic derivatives or mixtures. These agents are also known for use in reducing the risk of undesirable blood coagulation in individuals having a tendency or risk of excessive blood clotting.
  • a clot lysis agent such as t-PA within several hours following a stroke is useful in the lysis of blood clots for an individual suffering from an ischemic disease, such as ischemic stroke.
  • t-PA and/or other clot lysis agents may also be administered to reduce the risk of undesirable blood clotting, for example during angiographic catheter procedures.
  • the invention is directed to methods for enhancing the lysis of coagulated blood, which methods comprise administering to coagulated blood a combination of a clot lysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof.
  • methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of a clot lysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof.
  • the invention is further directed to methods for reducing the risk of blood coagulation. These methods comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof.
  • the invention is directed to methods for enhancing the lysis of coagulated blood by administering a specific level of a clot lysis agent.
  • the specific level of clot lysis agent to be administered to the individual is based upon the apolipoprotein phenotype of the individual.
  • the invention is directed to methods for reducing the risk of blood coagulation by administering a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.
  • the methods according to the present invention are advantageous in the treatment of ischemic diseases by enhancing the lysis of coagulated blood and/or reducing the risk of excessive, undesirable blood clotting, particularly in individuals at risk of exhibiting excessive or undesirable blood clotting.
  • Fig. 1 depicts an enhancing effect of clot lysis in vitro through the administration of t-PA and Apo E2 as described in Example 2;
  • Fig. 2 depicts effects of clot lysis in vitro with respect to t-PA administration in conjunction with Apo E2 or Apo E4 as described in Example 2;
  • Fig. 3a depicts a lipophilic interaction of t-PA with Apo E2 observed by Thin Layer Chromatography (TLC) as described in Example 3;
  • Fig. 3b depicts a hydrophobic interaction of t-PA with Apo E4 observed by Thin Layer Chromatography (TLC) as described in Example 4;
  • Fig. 4 depicts the average EC 50 clot dissolution of t-PA in conjunction with Apo E2, Apo E3 and Apo E4 as described in Example 4.
  • the present invention is directed to methods for enhancing the lysis of coagulated blood by administering to coagulated blood a combination of a clot lysis agent and a lysis-enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof.
  • This invention also is directed to methods for reducing the risk of undesirable elevated levels of coagulated blood by administering to blood a combination of a clot lysis agent and a lysis-enhancing amount of Apo E2 or a therapeutic derivative thereof.
  • Current thrombolytic therapies are premised upon the administration of a clot lysis agent to lyse coagulated blood, for example after an ischemic disease is detected, or to prevent clot formation by administration of a clot lysis agent.
  • this invention is also directed to methods for enhancing the lysis of coagulated blood and to methods for reducing the risk of blood coagulation before formation by administering a specific level of clot lysis agent, wherein the specific level is based upon the apolipoprotein phenotype of the individual to be treated.
  • lysis of coagulated blood generally refers to the dissolution or destruction of a blood clot or thrombus.
  • coagulated blood generally refers to a clot of blood such that the blood is in the form of a soft semisolid or solid mass.
  • administering a clot lysis agent in "combination" with a lysis enhancing amount of apolipoprotein E2 or a therapeutic derivative of E2 generally refers to administering the products together, i.e., simultaneously, or in conjunction with one another, i.e., sequentially.
  • “Clot lysis agent” generally refers to any of the known thrombolytic agents which are used to enhance the lysis of blood clots. Known agents include, but are not limited to, TNK-t-PA, t-PA, reteplase, streptokinase, heparin, coumadin, Glib Ilia receptor blockers, therapeutic derivatives thereof, or mixtures thereof.
  • the clot lysis agent comprises tissue plasminogen activator (t-PA) or a derivative thereof.
  • Apolipuprotein E is known generally as a member of a family of lipid-associated proteins whose isoforms have been implicated as an important modifier of several neurologic, vascular and cardiovascular diseases. See Corder, et al. Science; 261 :921-3 (1993). Apo E has three common isoforms - E2, E3, and E4. These monomeric isoforms combine to make six Apo E phenotypes: E2/2, E2/3, and E2/4 (referred to as the E2 category), E3/3 (E3 category), and E4/3 and E4/4 (E4 category). See Payami, et al. JAMA; 271 : 1316-7 (1994); Polvikoski, et al.
  • E2 isoforms, E2/2, E2/3 and E2/4, referred to herein as Apo E2 are employed in the methods of the invention.
  • Therapeutic derivatives for example fragments of Apo E2 having the lysis enhancing activity, can also be administered.
  • therapeutic derivative generally refers to an Apo E2 fragment or chemical or structural analogue exhibiting the lysis-enhancing activity. For example, as is known in the art, one can isolate an Apo E protein and selectively degrade the protein to smaller peptides which are then screened to determine if they contain the lipophilic regions of the Apo E2 protein known to exhibit lipophilic properties.
  • the dosages of conventional clot lysis agents are generally based upon the individual's physiological characteristics and given medical condition.
  • a patient can be administered, for example, a range of t-PA of from about 0.1-10.0 mg/kg of blood.
  • a standard therapeutic dose of t-PA physiologically appropriate for thrombolytic therapy to be administered intravenously to blood over a one hour period is 0.9 mg/kg of blood.
  • “Lysis enhancing amount” generally refers to a quantitative amount of Apo E2 with which enhanced lysis activity of a conventional clot lysis agent is demonstrated.
  • Suitable doses of Apo E2, or its therapeutic derivative, necessary to enhance the lytic activity of a clot lysis agent such as t-PA will vary depending, inter alia, on physiological characteristics of the individual to be treated, including, but not limited to the Apo E phenotype of the individual, and on the given medical condition of the individual.
  • the Apo E2 or derivative is administered in an amount of about equal molar stoicheometry with the clot lysis agent to provide the lytic enhancing activity.
  • the equimolar amount is based on the amount of clot lysis agent administered and any additional amount of clot lysis agent inherent in the blood.
  • human blood typically contains about 0.0009 mg/1 t-Pa; this inherent amount would typically not influence the amount of Apo E or derivative which is administered.
  • Ischemic disease generally refers to a medical condition causing or resulting in a decrease in blood supply to a bodily organ, tissue, or location due to constriction or obstruction of blood vessels.
  • ischemic diseases comprise myocardial infarction, unstable angina, coronary artery thrombus, and peripheral vascular disease.
  • Peripheral vascular diseases typically refer to, inter alia, occlusions, retinopathy. and organ embolisms.
  • Organ embolism typically refers to the obstruction or occlusion of a blood vessel by an embolus within an organ system, for example, such as a pulmonary embolism.
  • thrombolytic therapy in the form of a clot lysis agent is often administered to enhance the lysis of coagulated blood.
  • some diseases and procedures that may be effected by such thrombolytic therapy include, angina, TIA pulmonary embolism arteriosclerosis heart attack, surgery, vascular surgery, grafts, organ transplants, limb reattachment, trauma pregnancy, child birth and post partum.
  • the methods for enhancing the lysis of coagulated blood or for reducing the risk of undesirable or excessive clot lysis according to the present invention may be employed in treatment of any such diseases or conditions.
  • the clot lysis agent and the Apo E2 are administered to an individual with an ischemic disease to enhance lysis of blood coagulation associated with the disease.
  • the clot lysis agent and the lysis-enhancing amount of Apo E2 are administered to reduce an individual's elevated level of coagulated blood.
  • these methods may be administered to reduce the level of blood coagulation associated with an ischemic disease.
  • methods of reducing the risk of blood coagulation can be administered, particularly in individuals at risk of developing undesirable or excessive clotting of blood.
  • These methods comprise administering to blood a combination of a clot lysis agent and a lysis-enhancing amount of Apo E2 or a therapeutic derivative thereof.
  • the combination can be administered to reduce the risk of the formation of an angiographic catheter clot.
  • a specific level of clot lysis agent is administered wherein the specific level is based upon the apolipoprotein phenotype of the individual.
  • the apolipoprotein phenotype of the individual will help the physician or care-giver conclude how much clot lysis agent will be required to obtain desired results. For example, less clot lysis agent will typically be required if the individual has an Apo E2 phenotype due to the clot lysis enhancing properties exhibited by the natural Apo E2.
  • the individual's apolipoprotein phenotype is determined prior to administering the specific level of clot lysis agent. Methods for determining apolipoprotein phenotype from blood or serum samples are known in the art and may be employed.
  • the clot lysis agent and the lysis-enhancing amount of Apo E2 are administered to an individual with post surgical complications of occlusion or clotting to enhance lysis of blood coagulation associated with the ischemic disease.
  • a specific level clot lysis agent can be administered to an individual based upon the apolipoprotein phenotype of the individual to enhance the lysis of coagulated blood associated with post surgical complications of occlusion or clotting.
  • the present example demonstrates the correlation of efficacy between Apo E2 and a clot lysis agent such as t-PA.
  • This example extended the study of results previously reported for the NINDS t-PA Stroke Study, which consisted of two sequential placebo-controlled, randomized, double-blind, multi-center clinical trials. See NINDS rt-PA Stroke Study Group. New Engl J Med; 333: 1581-1587 (1995); Brott, et al. Stroke; 20:864-70 (1989).
  • 409 individuals with a serum sample available were used as a study group in this example to demonstrate the enhanced lysis activity provided by a combination of Apo E2 and a clot lysis agent.
  • the phenotypes for the 409 individuals were as follows: Apo E2-2 (1%), Apo E2-3 (12%), Apo E2-4 (1%), Apo E3-3 (60%), Apo E3-4 (24%), and Apo E4-4 (2%).
  • Apo E2 on a binary measure of favorable outcome based on all four clinical outcome measures. See Tilley, et al. Stroke 1996;27:2136-42. An interaction between Apo E2 and treatment was considered significant if the p-value for interaction was ⁇ 0.10.
  • a time-from-stroke-onset-to-treatment by the treatment interaction was also added into the model for 3-month favorable outcome based upon previously demonstrated interaction of time and efficacy of t-PA therapy.
  • the adjusted log odds and 95% confidence intervals are presented comparing each Apo E2/treatment category (i.e. "Apo E2 (+)/Treatment (+)", “Apo E2 (+)/Treatment(-)", Apo E2(-)/Treatment(+)" to the reference group "Apo E2(-)/Treatment(-)".
  • the serum patient samples had been stored a median time of 38 months.
  • Table la shows the analysis of 3-month outcomes by treatment and by Apo E2 phenotype (yes (+)/no(-)) categories for the individual and global tests without adjusting for any covariates.
  • Individuals treated with t-PA who had an Apo E2 phenotype had a much greater likelihood of a favorable outcome by any of the four 3-month measures (range of odds ratios from 3.6 - 6.3) as compared to those individuals treated with placebo and without an E2 phenotype.
  • Baseline covariates Age (categorized), Rank of the actual weight, Rank of total dose delivered. Baseline pulse pressure, Prior aspirin use, NIHSS (5 groups), Hypertension, Race, Cardiac history, Age x NIHSS. Admission mean blood pressure (MBP), Age x Admission MBP, Diabetes and the variable: early CT finding. In looking at the relationship of the Apo E2 phenotype to intracerebral hemorrhage (ICH), no interactions were detected with respect to symptomatic ICH or all ICH within 36 hours of treatment onset (p-values > 0.40).
  • the Apo E2 phenotype was not significantly associated with either symptomatic ICH or with all ICH, even after adjustments for the other covariates in the primary hemorrhage model or the covariates unbalanced between groups with and without an Apo E2 phenotype (p- values > 0.30). See NINDS t-PA Stroke Study Group. Strofe;28:2109-2U8 (1997).
  • the lysis enhancing effect of Apo E2 is further demonstrated in vitro.
  • t-PA various methods for determining the function, action and or kinetics of t-PA. These include but are not limited to: measuring fibrin degradation fragments, clot lysis, clot weight, fluid evolution weight, clot times and others. Those experienced in the art will be familiar with these and other methods for assaying t-PA activity or clot degradation/formation etc.
  • the data from this study consists of a measurement of clot dissolution or lysis by measuring the amount of liquid liberated from the blood sample. This is an index of clot lysis and the clot lysis is stimulated by t-PA.
  • the normal therapeutic dosage of t-PA administered to individuals for thrombolytic therapy such as antistroke is 0.9 mg/kg (0.9 mg/1) of blood given intravenously over one hour.
  • the blood in this example was given a dose of t-PA at 1 mg/1 with increasing dosages of Apo E2 in micrograms/1.
  • the y-axis represents the rate of clot dissolution. As shown by the x-axis, increasing dosages of Apo E2 resulted in the enhancement of lytic behavior.
  • Figure 2 depicts the effect of clot lysis on the blood from a second individual with respect to t-PA administration in combination with Apo E2 or Apo E4.
  • the y-axis demonstrates in grams (g) the amount of clot lysis or dissolution measured.
  • the administration of t-PA alone at a level of 0.5 mg/1 blood shows that the level of clot lysis was substantially complete at 2.5g.
  • t-PA in conjunction with Apo E2 no significant change in lytic activity was recognized. This result was likely caused due to the individual's administration of aspirin or similar lytic agent before the blood sample was performed.
  • the amount of clot lysis was significantly inhibited, however, upon the administration of t-PA in conjunction with Apo E4.
  • the lysis inhibiting aspects of Apo E4 are disclosed in the inventors' application entitled Methods for Controlling the Lysis of Coagulated Blood with Apolipoprotein E4 (Apo E4), filed on even date herewith.
  • TLC Thin Layer Chromatography
  • a known concentration of t-PA in a first prepared solution is applied to a TLC plate and allowed to dry to measure molecular interaction.
  • a second solution equal molar amounts of t-PA and Apo E2 are employed and the solution is similarly applied to a second TLC plate and allowed to dry.
  • the TLC plates are put into migration chambers containing chloroform: ethanol in a 3:1 or 1 :1 ratio and allowed to migrate until the solvent front approaches 1 cm from the top of the plate.
  • the plates are removed from the chambers and allowed to dry in the fume cupboards.
  • the plates can be read with ninhydrin or uv light quenching.
  • the migration distances are marked and rf values reported.
  • Apo E isoproteins to modulate t-PA induced clot lysis is assessed using an in vitro clot assay system. This system uses the decrease in clot formation in the presence of t-PA to approximate the amount of clot lysis.
  • Blood samples are obtained from 18 volunteers and divided into three Apo E genotypes (6 patients in each group): E2 (E2/E2, E2/E3, E2/E4), E3 (E3/E3) and E4 (E3/E4,
  • EC 50 S are the effective concentrations of t-PA required to achieve 50% lysis of the clot.
  • TLC thin layer chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés qui permettent d'améliorer la lyse du sang coagulé et qui consistent à ajouter à du sang coagulé une combinaison d'un agent de lyse des caillots et une quantité, efficace pour améliorer la lyse, d'une apolipoprotéine E2 (Apo E2) ou d'un dérivé thérapeutique de cette dernière. Des procédés permettant de réduire le risque de coagulation sanguine consistent à ajouter au sang une combinaison d'un agent de lyse des caillots et une quantité, efficace pour améliorer la lyse, d'Apo E2 ou d'un dérivé thérapeutique de cette dernière. Des procédés additionnels permettant d'améliorer la lyse du sang coagulé consistent à administrer à un individu, un taux spécifique de l'agent de lyse des caillots, ce taux spécifique étant basé sur le phénotype d'apolipoprotéine de l'individu. D'autres procédés permettant de réduire le risque de coagulation sanguine consistent à ajouter au sang, un taux spécifique d'un agent de lyse des caillots, ledit taux étant fondé sur le phénotype d'apolipoprotéine de l'individu.
PCT/US2001/042719 2000-10-13 2001-10-12 Procedes de lyse du sang coagule avec de le phenotype d'apolipoproteine e2 WO2002030359A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002214644A AU2002214644A1 (en) 2000-10-13 2001-10-12 Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype
US10/398,880 US7208288B2 (en) 2000-10-13 2001-10-12 Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24040700P 2000-10-13 2000-10-13
US60/240,407 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002030359A2 true WO2002030359A2 (fr) 2002-04-18
WO2002030359A3 WO2002030359A3 (fr) 2002-07-18

Family

ID=22906387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042719 WO2002030359A2 (fr) 2000-10-13 2001-10-12 Procedes de lyse du sang coagule avec de le phenotype d'apolipoproteine e2

Country Status (3)

Country Link
US (1) US7208288B2 (fr)
AU (1) AU2002214644A1 (fr)
WO (1) WO2002030359A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097696A1 (fr) * 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methodes et compositions permettant de traiter une reperfusion ischemique
US7994120B2 (en) 2002-05-17 2011-08-09 Pfizer, Inc. Method of treating dyslipidemic disorder
US8119590B2 (en) 2001-09-28 2012-02-21 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030454A1 (fr) * 2000-10-13 2002-04-18 University Of Cincinnati Procedes de regulation de la lyse de sang coagule au moyen d'un phenotype d'apolipoproteine e4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO2002030454A1 (fr) * 2000-10-13 2002-04-18 University Of Cincinnati Procedes de regulation de la lyse de sang coagule au moyen d'un phenotype d'apolipoproteine e4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119590B2 (en) 2001-09-28 2012-02-21 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
WO2003097696A1 (fr) * 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methodes et compositions permettant de traiter une reperfusion ischemique
US7994120B2 (en) 2002-05-17 2011-08-09 Pfizer, Inc. Method of treating dyslipidemic disorder
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano

Also Published As

Publication number Publication date
US7208288B2 (en) 2007-04-24
AU2002214644A1 (en) 2002-04-22
US20040006017A1 (en) 2004-01-08
WO2002030359A3 (fr) 2002-07-18

Similar Documents

Publication Publication Date Title
Kakkar et al. Efficacy and safety of low‐molecular‐weight heparin (CY216) in preventing postoperative venous thrombo‐embolism: a co‐operative study
Levine et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism
Arcasoy et al. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence
Yasaka et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication
Klein et al. Tissue plasminogen activator for treatment of livedoid vasculitis
Been et al. Clinical effects and kinetic properties of intravenous APSAC—anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction
Been et al. Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.
Brommer et al. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man
Nabel et al. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction
Patel et al. Randomized, placebo‐controlled trial of oral phytonadione for excessive anticoagulation
Ebert et al. Long-term anticoagulant therapy after myocardial infarction: final report of the Veterans Administration Cooperative Study
Becker et al. Antithrombotic therapy: an abbreviated reference for clinicians
Mavromanoli et al. Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition
Marder A simple technique for the measurement of plasma heparin concentration during anticoagulant therapy
US7208288B2 (en) Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype
Marder et al. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism
Kültürsay et al. Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI
Wakita et al. Effects of anticoagulation on infarct size and clinical outcome in acute cardioembolic stroke
Benchimol et al. Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty
EA035358B1 (ru) Способ, набор и комбинация для лечения субъекта с симптомами инсульта или острого инфаркта миокарда
US7135305B2 (en) Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype
Nilsson et al. Δ4‐ethylestrenol in recurrent deep venous thrombosis
Ying et al. Temporal changes in circulating P-selectin, plasminogen activator inhibitor-1, magnesium, and creatine kinase after percutaneous coronary intervention
Saperas et al. Somatostatin compared with cimetidine in the treatment of bleeding peptic ulcer without visible vessel
Liu et al. Anti-inflammatory effects of tacrolimus in a rat model of acute pancreatitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10398880

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP